Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 7/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1682160 | 0.91 | MAPT (0.55) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL30789227 | 0.88 | MAOB (0.56) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL14616693 | 0.88 | MAOB (0.56) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL30141054 | 0.87 | MAOB (0.61) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL10147678 | 0.87 | MAPT (0.51) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL658101 | 0.87 | MAOB (0.61) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL8321731 | 0.86 | LMNA (0.57) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL18526952 | 0.81 | MAOB (0.51) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL25217712 | 0.81 | SLC5A1 (0.62) | MAPTCYP2C9CYP2C19MAOBLMNA | |
| SCHEMBL30384069 | 0.81 | SLC5A1 (0.62) | MAPTCYP2C9CYP2C19MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| US-9975869-B2 | Analogues of epicatechin and related polyphenols | SPHAERA PHARMA PVT. LTD. (IN) | 2018-05-22 | — | — | US | disclosed |
| US-20160143878-A1 | ANTIBACTERIAL AGENT | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20160039781-A1 | NOVEL ANALOGUES OF EPICATECHIN AND RELATED POLYPHENOLS | SPHAERA PHARMA PVT. LTD. (SG) | 2016-02-11 | — | — | US | disclosed |
| US-20150322033-A1 | ANTIBACTERIAL AGENT | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9181293-B2 | Method for the synthesis of aspalathin and analogues thereof | SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) | 2015-11-10 | — | — | US | disclosed |
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| US-20130018182-A1 | Method for the Synthesis of Aspalathin and Analogues Thereof | SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (ZA) | 2013-01-17 | — | — | US | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160143878-A1 | ANTIBACTERIAL AGENT | MRPL21, Q6ZSR9, NQO2 | MAPT 4732/4885TDP1 4131/4885L3MBTL1 1294/4885 |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | MAPT 84/4885TDP1 1281/4885L3MBTL1 3565/4885 |
| US-20130018182-A1 | Method for the Synthesis of Aspalathin and Analogues Thereof | ASPH, C9, ALDH3A1 | MAPT 3291/4885TDP1 2885/4885L3MBTL1 2398/4885 |
| US-20150322033-A1 | ANTIBACTERIAL AGENT | Q6ZSR9, MRPL21, NQO2 | MAPT 4733/4885TDP1 4209/4885L3MBTL1 1158/4885 |
| US-20160039781-A1 | NOVEL ANALOGUES OF EPICATECHIN AND RELATED POLYPHENOLS | PGC, TEAD3, TEAD4 | MAPT 1857/4885TDP1 3437/4885L3MBTL1 4805/4885 |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | MAPT 2799/4885TDP1 964/4885L3MBTL1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.